Login / Signup

Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.

Ayako BunMasayuki NagahashiMamiko KuroiwaMiki KomatsuYasuo Miyoshi
Published in: Breast cancer research and treatment (2023)
 cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.
Keyphrases
  • metastatic breast cancer
  • prognostic factors
  • induced apoptosis
  • cell cycle arrest
  • stem cells
  • signaling pathway
  • clinical trial
  • newly diagnosed